Mesoblast Ltd
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic… Read more
Mesoblast Ltd (MESO) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.028x
Based on the latest financial reports, Mesoblast Ltd (MESO) has a cash flow conversion efficiency ratio of -0.028x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.62 Million) by net assets ($597.44 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Mesoblast Ltd - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Mesoblast Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Mesoblast Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mesoblast Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
RBL Bank Limited
NSE:RBLBANK
|
0.037x |
|
ITC HOTELS LIMITED
NSE:ITCHOTELS
|
N/A |
|
Hyundai Autoever Corp
KO:307950
|
0.082x |
|
Danieli & C RSP
LSE:0N4I
|
0.099x |
|
Baoding Tianwei Baobian Electric Co Ltd
SHG:600550
|
0.172x |
|
NCC AB (publ)
PINK:NCCBF
|
0.250x |
|
SSR MINING INC. CDIS/1
F:ZSV1
|
N/A |
|
Delek US Holdings Inc
F:DEH
|
0.099x |
Annual Cash Flow Conversion Efficiency for Mesoblast Ltd (2005–2025)
The table below shows the annual cash flow conversion efficiency of Mesoblast Ltd from 2005 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $597.44 Million | $-49.95 Million | -0.084x | +17.12% |
| 2024-06-30 | $480.36 Million | $-48.46 Million | -0.101x | +19.98% |
| 2023-06-30 | $501.84 Million | $-63.27 Million | -0.126x | +4.74% |
| 2022-06-30 | $497.04 Million | $-65.78 Million | -0.132x | +27.87% |
| 2021-06-30 | $581.40 Million | $-106.68 Million | -0.183x | -78.83% |
| 2020-06-30 | $549.33 Million | $-56.37 Million | -0.103x | +14.59% |
| 2019-06-30 | $481.05 Million | $-57.79 Million | -0.120x | +12.56% |
| 2018-06-30 | $546.01 Million | $-75.01 Million | -0.137x | +25.64% |
| 2017-06-30 | $516.77 Million | $-95.47 Million | -0.185x | -10.89% |
| 2016-06-30 | $528.16 Million | $-88.00 Million | -0.167x | +16.58% |
| 2015-06-30 | $609.36 Million | $-121.71 Million | -0.200x | -39.49% |
| 2014-06-30 | $571.72 Million | $-81.86 Million | -0.143x | -66.87% |
| 2013-06-30 | $630.27 Million | $-54.08 Million | -0.086x | +43.03% |
| 2012-06-30 | $478.85 Million | $-72.12 Million | -0.151x | -171.78% |
| 2011-06-30 | $515.84 Million | $108.23 Million | 0.210x | +182.38% |
| 2010-06-30 | $37.92 Million | $-9.66 Million | -0.255x | +28.89% |
| 2009-06-30 | $25.79 Million | $-9.24 Million | -0.358x | -51.39% |
| 2008-06-30 | $26.22 Million | $-6.20 Million | -0.237x | +46.61% |
| 2007-06-30 | $20.54 Million | $-9.10 Million | -0.443x | -66.55% |
| 2006-06-30 | $11.97 Million | $-3.18 Million | -0.266x | -747.50% |
| 2005-06-30 | $19.26 Million | $-604.81K | -0.031x | -- |